Molecular regulation of cardiac hypertrophy

Area of Science:

• Cardiology
• Molecular Biology
• Pathophysiology

Background:

• Heart failure is a major cause of mortality, often linked to cardiac myocyte hypertrophy due to increased workload or disease.
• Cardiovascular conditions like myocardial infarction and obesity promote cardiac hypertrophy, leading to heart failure.
• Existing research suggests pathological cardiac hypertrophy may be reversible, driving drug discovery efforts.

Purpose of the Study:

• To review the molecular characteristics and signalling pathways of cardiac hypertrophy.
• To discuss potential therapeutic targets for preventing or reversing pathological cardiac hypertrophy.
• To explore the translation of molecular knowledge into pharmacological treatments for heart pathologies.

Main Methods:

• Review of genetic and cellular models of cardiac hypertrophy.
• Analysis of molecular signalling pathways regulating heart mass.
• Examination of aberrant gene expression, including the fetal gene program.
• Discussion of specific pathways: natriuretic peptides, adrenergic system, IL-6 cytokine family, MEK-ERK1/2, histone acetylation, calcium modulation, and microRNAs.

Main Results:

• Cardiac hypertrophy is characterized by specific molecular changes, including the re-expression of fetal genes.
• Multiple signalling pathways (e.g., natriuretic peptides, adrenergic system, microRNAs) are involved in controlling cardiac hypertrophy.
• Recent discoveries highlight microRNAs as crucial regulators of cardiac hypertrophy.
• Understanding these pathways provides insights into both physiological and pathological hypertrophy.

Conclusions:

• Pathological cardiac hypertrophy is a complex process involving numerous molecular signalling pathways.
• Targeting these pathways offers potential for novel therapeutic strategies.
• Translating current knowledge into effective pharmacological treatments for heart pathologies remains a significant challenge.